Medvient, Inc. — SEC Form D Filing
Medvient, Inc. filed an SEC Form D on July 10, 2026, reporting $90K raised in Healthcare Technology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- July 10, 2026
- Amount reported
- $90K
- Round stage
- Seed
- Industry
- Healthcare Technology
- Website
- https://medvient.co/
What the company does
Securities: Debt. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Medical practices lose significant revenue due to preventable claim denials, undisputepensed out-of-network claims, and other hidden inefficiencies in the billing process. This complex billing system makes it difficult for practices to recover money they have already earned.
Solution
Medvient offers a suite of products, including Medvient Recon, to help practices identify revenue leakage, analyze denials, and provide a 30-day recovery plan. Coming soon, Medvient Defense will address complex denial and payer disputes, and Medvient Clinical will assist with documentation and claim creation.
Why now
Medvient is being started at this moment due to the increasing complexity and volume of healthcare insurance audits, creating a critical need for technological solutions like IDR Defense Recon to accurately identify and recover lost revenue for companies.
Verdict
Investors backed Medvient for its promise of concrete revenue recovery in a known pain point, not for innovative technological breakthroughs. The implicit bet was on the immediate, tangible ROI for practice managers navigating complex billing, providing a clear value proposition. Upside was limited by the reliance on existing data structures and the potential for larger RCM players to integrate similar recovery modules, effectively commoditizing the niche rather than building a new category.
Source: SEC EDGAR Form D filing